{"id":"NCT01151852","sponsor":"Asan Medical Center","briefTitle":"Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT","officialTitle":"A Prospective, Double Blind, Randomized, Placebo-Controlled Phase III Trial of Imatinib Re-Challenge in Patients With Gastrointestinal Stromal Tumor Who Had Benefit From Prior Imatinib But Progression From Both Imatinib and Sunitinib","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-06","primaryCompletion":"2013-03","completion":"2013-03","firstPosted":"2010-06-29","resultsPosted":"2015-07-28","lastUpdate":"2020-01-14"},"enrollment":81,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Gastrointestinal Stromal Tumors"],"interventions":[{"type":"DRUG","name":"Imatinib","otherNames":["Glivec"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Imatinib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to compare the clinical outcomes following resumption of dosing (re-challenge) with Imatinib plus best supportive care versus placebo plus best supportive care in patients with advanced/incurable Gastrointestinal Stromal Tumors following failure of prior imatinib and sunitinib therapies.","primaryOutcome":{"measure":"Progression-free Survival","timeFrame":"up tp12 weeks","effectByArm":[{"arm":"Imatinib","deltaMin":1.8,"sd":null},{"arm":"Placebo","deltaMin":0.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":7},"locations":{"siteCount":1,"countries":["South Korea"]},"refs":{"pmids":["15365079","14645423","12181401","15767559","15451219","16624552","17046465","26699729","24140183"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":41},"commonTop":["Anemia","Edema","Anorexia","Fatigue","Neutropenia"]}}